Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM E BASRI

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1992778948
CMS profile
362990
Location
BRICK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,044.43

139 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM E BASRI

NPI 1992778948 · CMS profile ID 362990

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

BRICK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992778948?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM E BASRI, NPI 1992778948, CMS profile ID 362990. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992778948?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). WILLIAM E BASRI, NPI 1992778948, CMS profile ID 362990. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992778948?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
WILLIAM E BASRI, NPI 1992778948, CMS profile ID 362990, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1992778948?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

139 matching records · $2,044.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 139 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 139.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $24.2408/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137482505 CMS
ABBVIE INC. $8.4508/14/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104194194 CMS
Janssen Biotech, Inc. $9.3008/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078346458 CMS
Lilly USA, LLC $19.5108/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135513930 CMS
Celgene Corporation $11.1108/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101175852 CMS
Celgene Corporation $3.8308/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101175854 CMS
GENZYME CORPORATION $22.3408/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139992529 CMS
Lilly USA, LLC $21.9708/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135482175 CMS
ABBVIE INC. $8.2007/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103288511 CMS
Gilead Sciences, Inc. $17.4207/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133772329 CMS
Lilly USA, LLC $8.4907/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135441683 CMS
Celgene Corporation $10.0407/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101175848 CMS
Janssen Biotech, Inc. $18.5407/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078345555 CMS
PFIZER INC. $16.0107/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131869384 CMS
GENZYME CORPORATION $5.9407/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139992519 CMS
Janssen Biotech, Inc. $16.6907/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078345866 CMS
Celgene Corporation $10.0407/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101175846 CMS
Phathom Pharmaceuticals, Inc. $14.4907/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151038918 CMS
Janssen Biotech, Inc. $8.0106/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078345818 CMS
Celgene Corporation $15.3206/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101175844 CMS
Janssen Biotech, Inc. $21.8506/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078345933 CMS
ABBVIE INC. $15.4506/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103288509 CMS
PFIZER INC. $17.1106/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131685055 CMS
GENZYME CORPORATION $20.9606/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139992515 CMS
ABBVIE INC. $12.4906/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103288507 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.9606/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137482502 CMS
GENZYME CORPORATION $8.7205/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139992511 CMS
Lilly USA, LLC $19.6005/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135482173 CMS
Celgene Corporation $10.0405/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101175842 CMS
Janssen Biotech, Inc. $17.2605/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078346001 CMS
PFIZER INC. $5.2405/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132043262 CMS
PFIZER INC. $11.1605/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132043560 CMS
Celgene Corporation $10.0205/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101175840 CMS
Takeda Pharmaceuticals U.S.A., Inc. $7.2905/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137482498 CMS
ABBVIE INC. $16.1905/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103288505 CMS
Lilly USA, LLC $4.1904/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135482171 CMS
Janssen Biotech, Inc. $16.7904/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078346774 CMS
QOL Medical, LLC $15.6004/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147727466 CMS
ABBVIE INC. $16.1904/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103288503 CMS
Janssen Biotech, Inc. $13.0604/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078345873 CMS
Janssen Biotech, Inc. $5.3804/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078345852 CMS
QOL Medical, LLC $17.0604/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147727464 CMS
GENZYME CORPORATION $22.0504/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139992507 CMS
ABBVIE INC. $9.7104/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103288501 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.8704/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137482494 CMS
GENZYME CORPORATION $17.8004/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139992509 CMS
Celgene Corporation $11.1404/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101175836 CMS
Celgene Corporation $10.0204/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101175834 CMS
GENZYME CORPORATION $8.2904/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139992503 CMS
Janssen Biotech, Inc. $19.6604/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078345673 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,368.53 104
PY2020 $1,181.50 75
PY2021 $2,114.61 162
PY2022 $2,036.17 140
PY2023 $1,926.57 134
PY2024 $2,044.43 139
PY2025 $2,376.71 136

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $178,929.81 25
PY2023 Principal investigator $11,393.20 5
PY2022 Principal investigator $80,683.20 35

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Braintree Laboratories, Inc. $22,272.00 11/12/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC (AHCRO) - JACKSON
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204032
Principal investigator 1 Braintree Laboratories, Inc. $2,505.69 10/29/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC (AHCRO) - JACKSON
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203660
Principal investigator 1 Braintree Laboratories, Inc. $11,136.00 10/29/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC (AHCRO) - JACKSON
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203662
Principal investigator 1 Braintree Laboratories, Inc. $31,459.84 10/08/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC (AHCRO) - JACKSON
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203080
Principal investigator 1 Braintree Laboratories, Inc. $2,455.01 10/03/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC (AHCRO) - JACKSON
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202850
Principal investigator 1 Braintree Laboratories, Inc. $14,720.92 10/03/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC (AHCRO) - JACKSON
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202854
Principal investigator 1 Braintree Laboratories, Inc. $16,704.00 09/30/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC (AHCRO) - JACKSON
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202746
Principal investigator 1 Braintree Laboratories, Inc. $6,968.00 09/27/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC (AHCRO) - JACKSON
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202666
Principal investigator 1 Braintree Laboratories, Inc. $11,220.92 09/25/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC (AHCRO) - JACKSON
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202630
Principal investigator 1 Braintree Laboratories, Inc. $11,305.84 09/25/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC (AHCRO) - JACKSON
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202634
Principal investigator 1 Braintree Laboratories, Inc. $2,153.76 09/13/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC (AHCRO) - JACKSON
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202154
Principal investigator 1 Braintree Laboratories, Inc. $4,389.02 08/16/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC (AHCRO) - JACKSON
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120201778
Principal investigator 1 Braintree Laboratories, Inc. $5,982.11 08/01/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120201450
Principal investigator 1 Braintree Laboratories, Inc. $5,731.00 07/31/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC (AHCRO) - JACKSON
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120201336
Principal investigator 1 Braintree Laboratories, Inc. $8,991.28 07/19/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC (AHCRO) - JACKSON
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200950
Principal investigator 1 Amgen Inc. $176.96 06/10/2024 Non-covered Recipient Entity
ALIED DIGESTIV HLTHCLINIC
P2 UC No dispute reported 06/30/2026 1096312731
Principal investigator 1 Amgen Inc. $1,763.46 05/28/2024 Non-covered Recipient Entity
TANDEM-ALLIED CLINICAL RESEARCH
P2 UC No dispute reported 06/30/2026 1096312863
Principal investigator 1 Braintree Laboratories, Inc. $2,728.02 04/04/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199550
Principal investigator 1 Braintree Laboratories, Inc. $2,728.02 04/04/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199628
Principal investigator 1 Braintree Laboratories, Inc. $2,053.37 02/08/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120198700
Principal investigator 1 Braintree Laboratories, Inc. $2,053.37 02/08/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120198774
Principal investigator 1 Braintree Laboratories, Inc. $354.76 02/02/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120198544
Principal investigator 1 Braintree Laboratories, Inc. $354.76 02/02/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120198654
Principal investigator 1 Braintree Laboratories, Inc. $4,360.85 01/04/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120198102
Principal investigator 1 Braintree Laboratories, Inc. $4,360.85 01/04/2024 Non-covered Recipient Entity
ALLIED HEALTH CLINICAL RESEARCH ORGANIZATION LLC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120198294